Company Description

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors.

The company engages in the treatment of solid tumors through its proprietary LODER delivery platform.

Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.

The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Silexion Therapeutics Corp

Country	Israel
Founded	2008
Industry	Biotechnology
Sector	Healthcare
CEO	Ilan Hadar

Contact Details

Address: The Goldyne Savad Institute of Gene Therapy, Hadassah Hebrew University Medical Center Jerusalem, 9112001 Israel
Phone	972 2 674 3430
Website	silexion.com

Stock Details

Ticker Symbol	SLXN
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0002022416
ISIN Number	KYG1281K1067
SIC Code	2836

Key Executives

Name	Position
Ilan Hadar M.B.A.	Chairman and Chief Executive Officer
Mirit Horenshtein Hadar	Executive Vice President of Finance Affairs, Chief Financial Officer and Secretary
Dr. Mitchell Shirvan M.B.A., Ph.D.	Chief Scientific and Development Officer

Latest SEC Filings

Date	Type	Title
Nov 14, 2024	8-K	Current Report
Nov 14, 2024	10-Q	Quarterly Report
Nov 13, 2024	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Nov 1, 2024	8-K	Current Report
Oct 31, 2024	S-1	General form for registration of securities under the Securities Act of 1933
Oct 22, 2024	DEF 14A	Other definitive proxy statements
Oct 16, 2024	EFFECT	Notice of Effectiveness
Oct 16, 2024	424B3	Prospectus
Oct 15, 2024	UPLOAD	Filing
Oct 10, 2024	PRE 14A	Other preliminary proxy statements

View All SEC Filings